Merck announced the first presentation of interim data from the pivotal phase III KEYNOTE-048 trial investigating Keytruda as both monotherapy and in combination with chemotherapy for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe